Search

Your search keyword '"Koinzer, Stefan"' showing total 131 results
Start Over Author "Koinzer, Stefan"
131 results on '"Koinzer, Stefan"'

7. Effectiveness and safety of VISULAS® green selective laser trabeculoplasty: a prospective, interventional multicenter clinical investigation.

Author

Pillunat, Karin R., Kretz, Florian T. A., Koinzer, Stefan, Ehlken, Christoph, Pillunat, Lutz E., and Klabe, Karsten

Abstract

Purpose: To evaluate the effectiveness and safety of Selective Laser Trabeculoplasty (SLT) with the SLT mode of the VISULAS® green laser in patients with primary open-angle glaucoma (POAG). Methods: This prospective, interventional multicenter clinical investigation included patients with POAG who either needed a treatment escalation because the individual intraocular pressure (IOP) target was not met or treatment initiation and had an IOP ≥ 17 mmHg at baseline in the study eye. The study was conducted in five research centers across Germany. Approximately 100 laser applications were delivered to 360° of the trabecular meshwork. Glaucoma medications were not modified during the 3-month follow-up to allow evaluation of the sole effect of VISULAS® green with SLT. Efficacy outcomes were postoperatively absolute and relative IOP changes at 1 and 3 months. Safety outcomes analyzed the rate of intra- and postoperative adverse events. Results: Thirty-four eyes of 34 POAG patients were included. The overall mean number of preoperative glaucoma medications was 2.2 ± 1.4 in 29 treated eyes, 5 eyes were treatment naïve. Mean baseline IOP (mmHg) was 21.0 ± 2.69 and was reduced by − 3.53 ± 3.34 [95% CI − 4.61; − 2.45] and − 3.59 ± 3.41 [95% CI − 4.64; − 2.53] at the 1- and 3-month follow-up, respectively (p < 0.0001), with 48.5% of cases achieving a ≥ 20% IOP reduction at 3 months [95% CI = 30.8%; 66.5%]. The mean relative IOP reduction was − 16.4% and − 16.3% at 1 and 3 months, respectively (p < 0.0001). Potentially device- or procedure-related adverse events were mild to moderate and included 3 postoperative IOP-spikes and 6 reports regarding eye pain and discomfort. All were resolved without sequelae. Conclusions: SLT performed with the VISULAS® green laser achieved clinically significant additional IOP reductions in medically treated as well as in treatment naïve eyes with POAG and there were no relevant safety issues. The results are comparable to other reported SLT studies. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

8. Effectiveness and safety of VISULAS ® green selective laser trabeculoplasty: a prospective, interventional multicenter clinical investigation

Author

Pillunat, Karin R., Kretz, Florian T. A., Koinzer, Stefan, Ehlken, Christoph, Pillunat, Lutz E., Klabe, Karsten, Pillunat, Karin R., Kretz, Florian T. A., Koinzer, Stefan, Ehlken, Christoph, Pillunat, Lutz E., and Klabe, Karsten

Abstract

Purpose To evaluate the effectiveness and safety of Selective Laser Trabeculoplasty (SLT) with the SLT mode of the VISULAS ® green laser in patients with primary open-angle glaucoma (POAG). Methods This prospective, interventional multicenter clinical investigation included patients with POAG who either needed a treatment escalation because the individual intraocular pressure (IOP) target was not met or treatment initiation and had an IOP ≥ 17 mmHg at baseline in the study eye. The study was conducted in five research centers across Germany. Approximately 100 laser applications were delivered to 360° of the trabecular meshwork. Glaucoma medications were not modified during the 3-month follow-up to allow evaluation of the sole effect of VISULAS ® green with SLT. Efficacy outcomes were postoperatively absolute and relative IOP changes at 1 and 3 months. Safety outcomes analyzed the rate of intra- and postoperative adverse events. Results Thirty-four eyes of 34 POAG patients were included. The overall mean number of preoperative glaucoma medications was 2.2 ± 1.4 in 29 treated eyes, 5 eyes were treatment naïve. Mean baseline IOP (mmHg) was 21.0 ± 2.69 and was reduced by − 3.53 ± 3.34 [95% CI − 4.61; − 2.45] and − 3.59 ± 3.41 [95% CI − 4.64; − 2.53] at the 1- and 3-month follow-up, respectively (p < 0.0001), with 48.5% of cases achieving a ≥ 20% IOP reduction at 3 months [95% CI = 30.8%; 66.5%]. The mean relative IOP reduction was − 16.4% and − 16.3% at 1 and 3 months, respectively (p < 0.0001). Potentially device- or procedure-related adverse events were mild to moderate and included 3 postoperative IOP-spikes and 6 reports regarding eye pain and discomfort. All were resolved without sequelae. Conclusions SLT performed with the VISULAS ® green laser achieved clinically significant additional IOP reductions in medically treated as well as in treatment naïve eyes with POAG and there were no relevant safety issues. The results are comparable to other reported SLT studies.

Published
2022

23. Power-controlled temperature guided retinal laser therapy

Author

Baade, Alexander, primary, von der Burchard, Claus, primary, Lawin, Meike, primary, Koinzer, Stefan, primary, Schmarbeck, Benedikt, primary, Schlott, Kerstin, primary, Miura, Yoko, primary, Roider, Johann, primary, Birngruber, Reginald, primary, and Brinkmann, Ralf, primary

Published
2017
Full Text
View/download PDF

24. Unterschwellige Laserkoagulation mit einem Standardlaser bei RCS – eine Fallserie

Author

Koinzer, Stefan, Treumer, F., Purtskhvanidze, K., and Roider, J.

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Einleitung: Wir demonstrieren an einer Fallserie, wie unterschwellige Laserphotokoagulation mit einem continuous wave (CW) Laser möglich ist. Methoden: 5 Augen von 5 Patienten mit chronischer Retinopathia centralis serosa (RCS), lokalisierter angiographischer Leckage und subfovealer subretinaler[zum vollständigen Text gelangen Sie über die oben angegebene URL], 29. Jahrestagung der Retinologischen Gesellschaft

Published
2016
Full Text
View/download PDF

36. Correlation of temperature rise and optical coherence tomography characteristics in patient retinal photocoagulation

Author

Koinzer, Stefan, primary, Schlott, Kerstin, additional, Portz, Lea, additional, Ptaszynski, Lars, additional, Baade, Alexander, additional, Bever, Marco, additional, Saeger, Mark, additional, Caliebe, Amke, additional, Denner, Renè, additional, Birngruber, Reginald, additional, Brinkmann, Ralf, additional, and Roider, Johann, additional

Published
2012
Full Text
View/download PDF

46. Oxidative Stress Induces Biphasic ERK1/2 Activation in the RPE with Distinct Effects on Cell Survival at Early and Late Activation.

Author

Koinzer, Stefan, Reinecke, Kirstin, Herdegen, Thomas, Roider, Johann, and Klettner, Alexa

Subjects
*CELL death, *RHODOPSIN, *OXIDATIVE stress, *OXIDATION-reduction reaction, *GENETICS of retinal degeneration, *MITOGEN-activated protein kinases, *LABORATORY mice
Abstract

Purpose: Oxidative stress is considered a major factor in the deterioration of retinal pigment epithelium (RPE) cells in dry age-related macular degeneration (AMD). The MAPK ERK1/2 can be activated by oxidative stress, may exert both pro- and anti-apoptotic functions, and has recently been proposed as a major factor in RPE degeneration in atrophic changes. Nrf2 is a master regulator of oxidative stress defense and ERK1/2 is an upstream activator of Nrf2. In this study, we investigate the participation of ERK1/2 in oxidative stress pathways in connection with Nrf2. Methods: Nrf2 knock-out and wild-type primary RPE cells were prepared from mouse eyes. Oxidative stress was induced by different concentrations of t-butylhydroperoxide. Mitogen-activated protein kinases (MAPKs) were blocked by commercially available inhibitors (SB203580, U0126, SP600125). Cell viability was determined by MTT assay. ERK1/2 expression and activation were assessed by Western blotting. Results: Oxidative stress induced concentration dependent cell death, which occurred at lower concentrations in Nrf2 knock-out RPE. Western blot analysis displayed a biphasic activation of ERK1/2 in murine wild-type RPE and the inhibition of late, but not early activation of ERK1/2 exerted protection in wild-type murine RPE cells. The biphasic activation of ERK1/2 is lost in Nrf2 knock-out mice, and inhibition of ERK1/2 was generally protective. The inhibition of MAPK JNK or p38 exerted no protection, irrespective of Nrf2. Conclusion: RPE cells display a biphasic activation of ERK1/2 after oxidative insult, of which the late activation is pro-apoptotic. The biphasic activation is lost in Nrf2 knock-outs, suggesting that early ERK1/2 activation may be connected to Nrf2 signaling. In addition, ERK1/2 activation in Nrf2 knock-outs mediates oxidative stress-induced cell death. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

50. Deferoxamine mesylate is toxic for retinal pigment epithelium cells in vitro, and its toxicity is mediated by p38.

Author

Klettner, Alexa, Koinzer, Stefan, Waetzig, Vicki, Herdegen, Thomas, and Roider, Johann

Subjects
DEFEROXAMINE, AMINES, METHANESULFONATES, ORGANOSULFUR compounds, MITOGEN-activated protein kinases, RHODOPSIN, THERAPEUTICS
Abstract

Deferoxamine mesylate is clinically used as a chelating agent but might induce retinopathy. To evaluate its effect on the retinal pigment epithelium (RPE), porcine RPE cells were stimulated with deferoxamine. Cell death was assessed with trypan blue exclusion assay. To investigate the pathway of cell death, the mitogen-activated protein kinases (MAPKs) Erk, JNK, and p38 were inhibited with U0126, SP600125, and SB203580, respectively. Their activity was determined by Western blot. Deferoxamine induces significant cell death in RPE cells, accompanied by phosphorylation of p38 and Erk. Inhibition of p38 attenuates cell death. In conclusion, deferoxamine is directly toxic on RPE cells, its toxicity depending on p38. [ABSTRACT FROM AUTHOR]

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results